| |
Univariable analysis
|
Multivariable analysis
|
|---|
|
OR (95% CI)
|
P
|
AOR (95% CI)
|
P
|
|---|
|
Age (year, mean ± SD)
|
0.99 (0.97–1.01)
|
0.505
| | |
|
Sex
|
|
Male
|
Ref
| | | |
|
Female
|
0.81 (0.46–1.42)
|
0.458
| | |
|
Histopathological type
|
|
Adenocarcinoma
|
Ref
| | | |
|
Mucinous adenocarcinoma
|
1.42 (0.42–4.85)
|
0.575
| | |
|
Differentiation grade
|
|
Well or moderate
|
Ref
| | | |
|
Poor
|
2.19 (0.69–7.01)
|
0.185
| | |
|
cT status
|
|
cT2
|
Ref
| | | |
|
cT3
|
1.02 (0.28–3.76)
|
0.971
| | |
|
cT4
|
0.78 (0.20–3.04)
|
0.722
| | |
|
cN status
|
|
cN0
|
Ref
| | | |
|
cN1
|
1.15 (0.54–2.42)
|
0.715
| | |
|
cN2
|
2.03 (0.96–4.30)
|
0.065
| | |
|
Tumour location
|
|
< 5 cm
|
Ref
| | | |
|
5–10 cm
|
0.83 (0.50–1.40)
|
0.491
| | |
|
> 10 cm
|
0.97 (0.16–6.00)
|
0.974
| | |
|
CEA level
|
|
Normal
|
Ref
| | | |
|
Abnormal
|
0.88 (0.53–1.47)
|
0.636
| | |
|
CA199 level
|
|
Normal
|
Ref
| | | |
|
Abnormal
|
1.28 (0.68–2.40)
|
0.450
| | |
|
Time interval between nCRT and surgery
|
|
< 7 weeks
|
Ref
| | | |
|
7–10 weeks
|
2.74 (0.79–9.56)
|
0.113
| | |
|
> 10 weeks
|
3.94 (1.16–13.4)
|
0.028
| | |
|
Chemotherapeutic regimen
|
|
5-fluorouracil
|
Ref
| |
Ref
| |
|
Capecitabine
|
0.52 (0.19–1.40)
|
0.194
|
0.45 (0.16–1.28)
|
0.134
|
|
FOLFOX
|
2.68 (1.27–5.68)
|
0.010
|
2.93 (1.33–6.46)
|
0.007
|
|
Other regimens
|
1.36 (0.51–3.61)
|
0.541
|
1.53 (0.55–4.28)
|
0.415
|
|
Neoadjuvant radiotherapy dose
|
|
< 45 Gy
|
Ref
| |
Ref
| |
|
≥ 45 Gy
|
3.71 (1.38–10.0)
|
0.006
|
5.25 (1.84–14.9)
|
0.002
|
|
TSR (three categery)
|
|
Low
|
Ref
| |
Ref
| |
|
Intermediate
|
0.60 (0.32–1.14)
|
0.121
|
0.45 (0.22–0.90)
|
0.025
|
|
High
|
0.40 (0.21–0.76)
|
0.005
|
0.32 (0.16–0.65)
|
0.002
|
- Abbreviation: TSR tumour-stroma ratio
